Management & Regulatory

How Can Patients Keep Weight Off After GLP-1 Injections?
Management & Regulatory How Can Patients Keep Weight Off After GLP-1 Injections?

The pharmaceutical landscape has shifted from a race for rapid weight loss toward a complex struggle to maintain results as patients transition away from intensive injectable therapy. While medications like Zepbound and Wegovy have provided the tools to reach target weights, the medical community

What Should You Know Before Joining a Clinical Trial?
Management & Regulatory What Should You Know Before Joining a Clinical Trial?

The rapid acceleration of medical breakthroughs in recent years has transformed clinical trials from a last-resort option into a sophisticated avenue for accessing cutting-edge healthcare solutions. These research studies represent the essential bridge between theoretical laboratory discoveries and

TB Screening Controls Predict Five-Year Mortality Risk
Management & Regulatory TB Screening Controls Predict Five-Year Mortality Risk

In the evolving landscape of biopharmaceuticals and clinical diagnostics, the ability to predict long-term health outcomes through routine testing is becoming a reality. Ivan Kairatov, a seasoned expert in biotechnology and research development, joins us to discuss a groundbreaking study published

Synplogen Leads the Way in Advanced Synthetic DNA Production
Management & Regulatory Synplogen Leads the Way in Advanced Synthetic DNA Production

Synthetic biology has undergone a profound transformation, evolving from a speculative academic discipline into the foundational infrastructure of a new global bio-economy. As the international community intensifies its efforts to achieve carbon neutrality and pioneer personalized medical

Birth Weight Predicts Kidney Resilience in Adult Athletes
Management & Regulatory Birth Weight Predicts Kidney Resilience in Adult Athletes

The physiological capacity of a modern ultramarathon runner might not be determined solely by thousands of grueling training miles but rather by the delicate window of biological development occurring within the final weeks of gestation. This revelation is fundamentally altering the landscape of

Entrada Stock Plunges 55% on Disappointing DMD Trial Results
Management & Regulatory Entrada Stock Plunges 55% on Disappointing DMD Trial Results

The precarious balance between scientific promise and clinical reality was shattered this week when Entrada Therapeutics watched more than half of its market capitalization evaporate following underwhelming trial results. This dramatic 55% collapse highlights the unforgiving nature of the

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later